[蛋白转化酶亚提利辛/凯类型9对血小板激活与败血症相关的影响]
Yuru Gao1, Jing Wang1, Xiao Huang1
1Department of Critical Care Medicine, the Affiliated Hospital, Binzhou Medical University, Binzhou 256603, Shandong, China.
Zhonghua wei zhong bing ji jiu yi xue
|August 18, 2023
概括
高水平的蛋白转化酶亚素/素9型 (PCSK9) 与败血症患者血小板数量下降相关. 抑制PCSK9可能为败血症诱导的血小板缺血提供治疗策略.
科学领域:
- 生物医学研究的研究.
- 败血症的病理生理学
- 血液学 血液学 血液学
背景情况:
- 败血症是一种危及生命的疾病,其特点是宿主对感染的反应失调.
- 血小板缺血,败血症的常见并发症,与死亡率增加有关.
- 与败血症相关的血小板激活中,蛋白转化酶亚提利辛/素9型 (PCSK9) 的作用尚不清楚.
研究的目的:
- 调查PCSK9水平与血症中血小板激活之间的关联.
- 探索PCSK9抑制对败血症诱导的血小板缺血的潜在治疗效果.
主要方法:
- 一项前性临床研究,涉及败血症患者和健康对照组.
- 在小鼠中使用脂多糖 (LPS) 诱导的败血症模型进行动物实验.
- 测量血清PCSK9和血小板计数,血小板激活标记 (CD62P,CD40L) 通过ELISA,流细胞计和西式涂抹.
主要成果:
- 与健康对照人群相比,败血症患者的PCSK9水平显著提高,血小板数量降低.
- 在败血症患者中,PCSK9水平和血小板计数之间观察到显著的负相关性.
- 在小鼠中抑制PCSK9降低了肺炎,血小板聚合和血小板激活标志物.
结论:
- PCSK9在败血症期间促进血小板激活起作用.
- 抑制PCSK9可能是一个有前途的治疗途径,用于管理与败血症相关的血小板衰竭.
更多相关视频
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
530
05:49Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
Published on: November 29, 2024
615
相关概念视频
Formation of the Platelet Plug
6.7K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
6.7K
Extrinsic and Intrinsic Pathways of Hemostasis
8.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.3K
Structure and Function of Platelets
1.2K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.2K
Clot Retraction and Fibrinolysis
6.5K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.5K
Introduction to Hemostasis
8.3K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.3K
Coagulation
7.1K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
7.1K
